Literature DB >> 16116225

Inhibition of neutrophil elastase by alpha1-protease inhibitor at the surface of human polymorphonuclear neutrophils.

Brice Korkmaz1, Sylvie Attucci, Marie-Lise Jourdan, Luiz Juliano, Francis Gauthier.   

Abstract

The uncontrolled proteolytic activity in lung secretions during lung inflammatory diseases might be due to the resistance of membrane-bound proteases to inhibition. We have used a new fluorogenic neutrophil elastase substrate to measure the activity of free and membrane-bound human neutrophil elastase (HNE) in the presence of alpha1-protease inhibitor (alpha1-Pi), the main physiological inhibitor of neutrophil serine proteases in lung secretions. Fixed and unfixed neutrophils bore the same amounts of active HNE at their surface. However, the HNE bound to the surface of unfixed neutrophils was fully inhibited by stoichiometric amounts of alpha1-Pi, unlike that of fixed neutrophils. The rate of inhibition of HNE bound to the surface of unfixed neutrophils was the same as that of free HNE. In the presence of alpha1-Pi, membrane-bound elastase is almost entirely removed from the unfixed neutrophil membrane to form soluble irreversible complexes. This was confirmed by flow cytometry using an anti-HNE mAb. HNE activity rapidly reappeared at the surface of HNE-depleted cells when they were triggered with the calcium ionophore A23187, and this activity was fully inhibited by stoichiometric amounts of alpha1-Pi. HNE was not released from the cell surface by oxidized, inactive alpha1-Pi, showing that active inhibitor is required to interact with active protease from the cell surface. We conclude that HNE activity at the surface of human neutrophils is fully controlled by alpha1-Pi when the cells are in suspension. Pericellular proteolysis could be limited to zones of contact between neutrophils and subjacent protease substrates where natural inhibitors cannot penetrate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116225     DOI: 10.4049/jimmunol.175.5.3329

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Neutrophil serine proteases fine-tune the inflammatory response.

Authors:  Christine T N Pham
Journal:  Int J Biochem Cell Biol       Date:  2007-11-29       Impact factor: 5.085

3.  A Pulmonary Perspective on GASPIDs: Granule-Associated Serine Peptidases of Immune Defense.

Authors:  George H Caughey
Journal:  Curr Respir Med Rev       Date:  2006-08

4.  Aggregated neutrophil extracellular traps resolve inflammation by proteolysis of cytokines and chemokines and protection from antiproteases.

Authors:  Jonas Hahn; Christine Schauer; Christine Czegley; Lasse Kling; Lenka Petru; Benjamin Schmid; Daniela Weidner; Christiane Reinwald; Mona H C Biermann; Stefan Blunder; Jürgen Ernst; Adam Lesner; Tobias Bäuerle; Ralf Palmisano; Silke Christiansen; Martin Herrmann; Aline Bozec; Robert Gruber; Georg Schett; Markus H Hoffmann
Journal:  FASEB J       Date:  2018-08-21       Impact factor: 5.191

5.  Alpha-1 Antitrypsin-Deficient Macrophages Have Increased Matriptase-Mediated Proteolytic Activity.

Authors:  Karina Krotova; George W Marek; Rejean L Wang; George Aslanidi; Brad E Hoffman; Nazli Khodayari; Farshid N Rouhani; Mark L Brantly
Journal:  Am J Respir Cell Mol Biol       Date:  2017-08       Impact factor: 6.914

Review 6.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

7.  Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils.

Authors:  Brice Korkmaz; Jérôme Jaillet; Marie-Lise Jourdan; Alexandre Gauthier; Francis Gauthier; Sylvie Attucci
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

8.  Neutrophil surface presentation of the anti-neutrophil cytoplasmic antibody-antigen proteinase 3 depends on N-terminal processing.

Authors:  S von Vietinghoff; C Eulenberg; M Wellner; F C Luft; R Kettritz
Journal:  Clin Exp Immunol       Date:  2008-06       Impact factor: 4.330

9.  New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases.

Authors:  Carla Guarino; Monika Legowska; Christophe Epinette; Christine Kellenberger; Sandrine Dallet-Choisy; Marcin Sieńczyk; Guillaume Gabant; Martine Cadene; Jérôme Zoidakis; Antonia Vlahou; Magdalena Wysocka; Sylvain Marchand-Adam; Dieter E Jenne; Adam Lesner; Francis Gauthier; Brice Korkmaz
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

10.  Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.

Authors:  Marie-Louise Zani; Kévin Baranger; Nicolas Guyot; Sandrine Dallet-Choisy; Thierry Moreau
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.